Cargando…
Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment. Erdafitinib, a potent and selective pan-FGFR tyrosine kinase inhibitor, has been confirmed to be effective for the treatment of LADC; however, the...
Autores principales: | Meng, Xinmin, Zhu, Xue, Ji, Jiali, Zhong, Hongqin, Li, Xiyue, Zhao, Hongqing, Xie, Guijuan, Wang, Ke, Shu, Hong, Wang, Xun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573074/ https://www.ncbi.nlm.nih.gov/pubmed/36235266 http://dx.doi.org/10.3390/molecules27196733 |
Ejemplares similares
-
Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
por: Ji, Jiali, et al.
Publicado: (2022) -
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020) -
Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022) -
Bronchoscopic treatment of multiple bronchial myelolipomas: a case report and literature review
por: Ji, Jiali, et al.
Publicado: (2023) -
PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells
por: de Souza, Ludmilla Regina, et al.
Publicado: (2014)